Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study

Introduction Sleep-disordered breathing (SDB) is a major comorbidity in idiopathic pulmonary fibrosis (IPF) and is associated with a poor outcome. There is a lack of knowledge regarding the impact of SDB treatment on IPF. We assessed at one year: (1) the effect of CPAP and/or nocturnal oxygen therapy on IPF regarding lung function, blood mediators, and quality of life; (2) adherence to SDB treatment and SDB changes. Methodology This is a prospective study of consecutive newly diagnosed IPF patients initiating anti-fibrotic treatment. Lung function, polysomnography, blood tests and quality of life questionnaires were performed at inclusion and after one year. Patients were classified as obstructive sleep apnoea (OSA), central sleep apnoea (CSA), and sleep-sustained hypoxemia (SSH). SDB therapy (CPAP and/or nocturnal oxygen therapy) was initiated if needed. Results Fifty patients were enrolled (36% had OSA, 22% CSA, and 12% SSH). CPAP was started in 54% of patients and nocturnal oxygen therapy in 16%. At one-year, polysomnography found improved parameters, though 17% of patients had to add nocturnal oxygen therapy or CPAP, while 33% presented SDB onset at this second polysomnography. CPAP compliance at one year was 6.74 h/night (SD 0.74). After one year, matrix metalloproteinase-1 decreased in OSA and CSA (p = 0.029; p = 0.027), C-reactive protein in OSA (p = 0.045), and surfactant protein D in CSA group (p = 0.074). There was no significant change in lung function. Conclusions Treatment of SBD with CPAP and NOT can be well tolerated with a high compliance. IPF patients may exhibit SDB progression and require periodic re-assessment. Further studies to evaluate the impact of SDB treatment on lung function and serological mediators are needed. Supplementary Information The online version contains supplementary material available at 10.1186/s12931-024-02871-6.

OSA and intermittent hypoxemia have been associated with ILD and an increment in the blood mediators of pulmonary interstitial remodelling and alveolar epithelial damage [14,[16][17][18].The progression of pulmonary fibrosis has been associated with the development of SDB through a mechanism that is still under debate [14,[19][20][21].
The treatment of SDB in IPF patients seems to improve quality of life and prognosis despite the scarce number of studies [11,22,23].Some methodological limitations include the absence of a generalized use of antifibrotic drug therapy [4,5] and self-selection bias owing to a high refusal rate and poor compliance with continuous positive airway pressure (CPAP) [24].There is limited data regarding the effect of using nocturnal oxygen therapy (NOT) in ILD patients and, to the best of our knowledge, there is no data regarding the effect of treating CSA in patients with ILD [25][26][27].
Therefore, this study of IPF patients aimed to assess: (1) the impact of personalized SDB treatment by CPAP and/or nocturnal oxygen therapy on lung function, blood mediators and quality of life; (2) tolerance of and adherence to SBD treatment and sleep-disordered breathing changes after one year of treatment and follow-up.

Methodology
This is a prospective pilot study of consecutive newly diagnosed IPF patients who were systematically studied for SBD and treated with CPAP and/or NOT depending on the type of SDB.Inclusion criteria was a confident IPF diagnosis by a multidisciplinary committee [2,3].Exclusion criteria included other life-threatening or unstable diseases.
Polysomnography (PSG), pulmonary function test, 6-minute walking test (6MWT), blood test, and questionnaires were performed at baseline and after one year.SDBs were classified as previously described [7]: (A) OSA when the apnoea-hypopnea index (AHI) was ≥ 15/h and obstructive events were predominant (≥ 50%); (B) CSA when AHI ≥ 15/h and there were predominant central events; (C) sleep sustained hypoxemia (SSH) when total sleep time under SpO2 88% (TST88) > 5 min and AHI < 15/h; (D) No-SDB when AHI < 15/h and TST88 ≤ 5 min.PSG at one year was performed under treatment if the patients was receiving it or basally if no treatment had been started.
Blood mediators included C-reactive protein (CRP), lactate dehydrogenase (LDH), N-terminal pro-B-type natriuretic peptide, interleukin 6 (IL-6), matrix metalloproteinase-1 (MMP-1), MMP-7, MMP-9, surfactant protein D (SP-D), tenascin-c large, Krebs von den Lungen 6 (KL-6), advanced glycation end-products (AGEs), and receptor of AGEs (RAGEs).Sleep quality and sleep habits questionnaires, the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire short version, EuroQol 5D-5 L, and the King's Brief Interstitial Lung Disease questionnaire were analysed.Comorbidities were assessed through the Beck Depression Inventory-II, the 7-item Generalized Anxiety Disorder Scale and the Gastroesophageal Reflux Disease Questionnaire.All patients received anti-fibrotic medication (nintedanib or pirfenidone) after the diagnosis and at least two weeks before the first blood sample was obtained.
The SDB treatment decision was based on the particular SDB (Fig. 1).Patients with moderate or severe OSA were treated with CPAP after a home autoCPAP titration [28,29].For those with moderate or severe CSA the treatment was individualized: they underwent manual CPAP titration and started CPAP if events decreased ≥ 50% [30]; if events did not decrease > 50%, servoventilation or oxygen therapy were considered and decided in each individualized case depending on IAH severity and the degree of nocturnal hypoxemia.Patients with nocturnal hypoxia using the criterion TST88 ≥ 5 min, started nocturnal oxygen therapy (NOT) [31,32].After one month of SDB treatment, patients with TST88 ≥ 5 min were re-assessed by nocturnal pulse-oximetry.Clinical follow-up following the standard of care assessment for IPF treatment and the SDB treatment by specialist nurses was performed at one, three, six and 12 months.

Statistics
Continuous variables were presented with mean and standard deviation, except for those with asymmetry or lack of normality, which were described with median and interquartile range.Categorical variables were reported as the number of cases and the percentage of the total.Paired t-tests were used for normally distributed variables, the Wilcoxon signed-rank test for non-normally distributed variables and the McNemar test for categorical variables.Using logistic regression models, the crude effect and the effect adjusted by forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO) and age were analysed.Statistical analyses were performed with R software version 4.2.1 or higher and STATA 17.

Study population
Fifty patients were enrolled (Table 1) and 72% were male.Mean age was 72.6 years and only 28% of cases were obese (BMI > 30 kg/m2).The sleep study identified 70% of patients as having some type of SDB encompassing 36% OSA, 22% CSA and 12% SSH.The baseline characteristics have been previously reported in more detail [14].Importantly, CSA cases were detected by coding nonobstructive hypopneas and these patients presented a predominance of hypopneas, compared to apnoeas, and did not present periodic breathing.CPAP was started in all OSA patients and 82% of CSA patients (nine patients), while NOT was initiated in SSH patients and 18% of CSA patients (two patients) (Table 2).Two patients died during follow-up (one OSA and one CSA).

Changes in lung function, blood mediators and QoL
Data are summarized in Table 3 according to SBD classification.At baseline, the mean FVC was lower in the SSH group (below 80%).After one year, lung function did not significantly change.Regarding the higher serum concentration of MMP-1 at baseline (Fig. 2) in the OSA and CSA groups, a significant decrease was observed after one year (p = 0.029 and p = 0.027, respectively).Furthermore, patients with OSA also showed a significant decrease of CRP in blood samples (p = 0.045) and the CSA group showed a trend to reduction of SP-D (p = 0.07).No significant differences were found when comparing the 1-year changes in lung function and blood mediators with the non-SBD group.The questionnaires (Supplemental Table 1) showed a significant improvement in ESS in OSA patients, with no other relevant changes.

Polysomnographic changes
The PSG study under SDB treatment at 1-year compared to the baseline showed a significant decrease in AHI and TST90 in the OSA and CSA groups, and a non-significant increase in mean oxygen saturation in the SHH group.The No-SDB group showed a significant decrease only in lowest oxygen saturation in basal PSG at one year.Concerning sleep phases, only the OSA group had a significant decrease in N1 (% TST).
The PSG study under SBD treatment at one year also revealed the need to add NOT to CPAP in two out of 16 OSA group patients and three out of nine patients in the CSA group (Table 2).CPAP was added to one patient in the SSH group initially treated with NOT.In the non-SDB group, the sleep study was repeated without treatment and it disclosed the existence of SDB in five out of 15 patients, requiring starting CPAP in three and NOT in two patients.The changes at one year in FVC, DLCO and weight in this group were not predictive of SDB progression in a logistic model.

SDB treatment compliance, side effects and patient satisfaction
CPAP compliance at one year was 6.74 h/night (SD 0.74) and all patients had a compliance higher than 5 h/night.Mean CPAP pressure was 7 mmHg [IQR 6;9] (OSA group: 7 mmHg [IQR 6;8] and CSA group: 8 mmHg [IQR 6;9]).The main reported adverse effect (Supplemental Table 2) was dry mouth, but no treatment discontinuation was associated with side effects.Regarding the Patient-Reported Experience Measures (PREMs) (Supplemental Table 3), satisfaction with the sleep study and SDB management was nearly 100%.

Discussion
This pilot study highlights the fact that the personalized management and treatment of SDBs with CPAP and NOT in patients with IPF is feasible, resulting in high CPAP compliance, few side effects and a high level of satisfaction.Most patients with SDBs do not present typical symptoms and a SDB may appear at any time during the follow-up.
There is very limited evidence regarding the treatment of SBD in IPF patients, evidence for OSA is scarce [33]; it was anecdotal for nocturnal hypoxia in ILD [25][26][27], and absent for CSA.Therefore, our proposal was a proof  of concept treating each condition individually according to the recommendations of the respective guidelines, and applying a personalized approach in order to achieve the optimal correction of each sleep disorder.Therefore, OSA was treated with CPAP with good results.As the treatment of CSA is not established for patients with FPI [30], as a general rule, we treated it with CPAP if manual CPAP titration decreased events ≥ 50%.This objective was not achieved in only two patients who had low basal IAH (16.0/h and 21.1/h) and a TST88 ≥ 5 min and who received nocturnal oxygen, achieving a good correction in control nocturnal oximetry.For this reason, no patient was submitted to serventilation.Patients with SSH were treated with NOT [32,34].This approach, and the cutoff points used to initiate each treatment, should be validated in future multicentre studies and larger real-world settings.
There were no significant differences in lung function after one year.Other studies treating patients with IPF and OSA by CPAP did not measure pulmonary function, but an improvement in survival was reported [11,22].However, a longer follow-up of larger a larger cohort and a control group would be required to better assess the potential impact of SDB treatment on IPF outcomes.
Increased levels of oxidative, inflammatory and profibrotic serological mediators were observed in IPF patients with SDB in previous studies [10,14,[16][17][18].Our previous study characterized different SDBs in IPF patients and their relationship with lung function and blood mediators [14].We hypothesized that different SDBs may be associated with distinct metabolic pathways.Apnoea groups presented higher levels of MMP-1 at baseline, which decreased significantly after one year of SDB treatment.MMP-1 is a profibrotic metalloproteinase related to hypoxia-inducible factor 1 (HIF-1) [35], which is increased in intermittent hypoxia, but not in sustained hypoxia [36].Furthermore, OSA and CSA present certain differences.As for non-ILD OSA patients [37], CRP was reduced after one year in the OSA group.On the other hand, SP-D was reduced to a figure close to statistical significance (p = 0.07) in CSA patients.SP-D is a blood mediator of epithelial alveolar tissue [38] associated with an increased death risk rate in IPF patients [39].SP-D may be up and down-regulated by HIF-1 in acute and persistent hypoxia, respectively [40], and higher levels of hypopnea index were associated with a decrease in SP-D blood levels [41].However, it is important to note that our study has an exploratory character and these changes cannot be extended to the treatment of SDB because many confounding factors, such as the initiation of antifibrotic treatment, may lead to erroneous conclusions.Future prospective randomized studies with longer follow-ups should evaluate these findings.
On the other hand, there is mounting evidence that non-physiological mechanical lung strain can produce an activation of pro-inflammatory and pro-fibrotic pathways that results in the progression of pulmonary fibrosis [42,43].Therefore, the long-term safety of CPAP treatment depending on the required positive end expiratory pressure (PEEP) levels should be considered in the future.Our data showed no significant changes in lung function.In addition, apnoea and hypopnea events in IPF patients have been also suggested as a pro-fibrotic mechanism [21,44,45].CPAP treatment could reduce repetitive lung strain and hypoxia-related damage.The accurate estimation of low CPAP pressure required may also have been a key factor in preventing mechanical damage and reducing the harmful effect of SDBs [43].
The high CPAP acceptance and compliance shown by the patients in our study contrasts with previous studies with IPF patients.In two similar studies, 8% and 16% of IPF candidate patients withdrew from CPAP treatment within the first month [11,23].In line with our data, a recent study did not report any CPAP refusal or discontinuation [22].Regarding CPAP compliance, 33% and 62% reported poor adherence (≥ 4 h/night) [11,22].Conversely, none of the patients in our series, had an adherence of less than five hours per night.The reasons for this good SDB treatment compliance are unknown, as they were not the focus of this study.However, a combination of comprehensive information on SDB, personalized SDB treatment and a close follow-up with an assessment of side effects may have had an influence.
One-third of patients without baseline SDB had some SDB at one year of control and had to start treatment, while 17% of patients treated for SBD had to increase their SDB treatment only one year later.Surprisingly, that was not associated with lung function decline or weight change.If this finding is confirmed in further series, sleep studies should be considered not only at diagnosis [8-10, 46, 47], but also during follow-up.
There were no significant differences in quality of life at one year.The COVID-19 outbreak may have negatively impacted quality of life results, which may explain the differences with regard to previous studies [11,22,23].However, the satisfaction score and PREMs of sleep screening, treatment and follow-up were high, suggesting that the process does not cause great inconvenience to patients.

Strengths and limitations
Limited sample size is the main limitation of this exploratory pilot study and constrained the statistical analyses, particularly when examining distinct SDB types such as the SSH group.Furthermore, although the enrolment of all patients after initiating antifibrotic drugs better enabled the assessment of SDB outcomes, its effect on  respiratory function and serum mediators could not be completely attributed to SDB treatment and the results should be considered with caution before being properly validated.All patients were treated with antifibrotics, whereas previous studies did not report or reported only partially on the use of antifibrotic drug treatment [11,22,23].The holistic diagnosis and management of SDB is another remarkable strength of the study, since it does not preclude different SDBs such as CSA [22], or treating nocturnal hypoxia with NOT and not only OSA by CPAP [11,22,23].Adherence may impact SDB outcomes, but due to the high level of compliance among the included patients, we were not able to analyse outcomes depending on the level of adherence.Finally, these results must be interpreted with caution, not only due to the limited number of patients, but also other potential confounding factors such as the absence of a control group with SDB but without treatment.

Conclusions
Our study suggests that a personalized selection of SDB treatment including CPAP and/or NOT involving a comprehensive follow-up of the therapy may be wellaccepted and achieve high compliance.SDB may appear or increase SDB treatment requirements only one year after their study.Therefore, not only sleep studies in IPF patients should be considered, but also periodic reassessment.Future randomized and longer follow-up studies are needed to evaluate the impact of SDB treatment on both lung function and biological mediators.